Company Profiles

driven by the PitchBook Platform

Kolltan Pharmaceuticals

Description

Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), which is currently in clinical development for the potential treatment of different solid tumors, and KTN0158, a monoclonal antibody targeting KIT, which is in clinical evaluation for cancer and preclinical evaluation for mast cell diseases.

2007

Founded

M&A

Status

11-50

Employees

M&A

Latest Deal Type

$235M

Latest Deal Amount

$140M

Total Amount Raised

Description

Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), which is currently in clinical development for the potential treatment of different solid tumors, and KTN0158, a monoclonal antibody targeting KIT, which is in clinical evaluation for cancer and preclinical evaluation for mast cell diseases.

Website:

www.kolltan.com

Ownership Status

Acquired/Merged

Financing Status

Formerly VC-Backed

Primary Industry

Drug Discovery

Primary Office

300 George Street Suite 530 New Haven, CT 06511United States +1 (203) 773-3000
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Kolltan Pharmaceuticals's full profile, request a free trial.

Kolltan Pharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Kolltan Pharmaceuticals Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Kolltan Pharmaceuticals Executive Team (11)

NameTitleBoard
Seat
Contact
Info
Gerald McMahon Ph.DChief Executive Officer, President & Board Member
Jane HendersonSenior Vice President & Chief Financial and Business Officer
Joseph Schlessinger Ph.DCo-Founder, Director and Chairman of Scientific Advisory Board
Lisa KamenDirector, Clinical Operations
Leigh FeigenbaumDirector, Regulatory & Clinical Affairs
Gerald McMahon Ph.D Chief Executive Officer, President & Board Member
Jane Henderson Senior Vice President & Chief Financial and Business Officer
Joseph Schlessinger Ph.D Co-Founder, Director and Chairman of Scientific Advisory Board
Lisa Kamen Director, Clinical Operations
Leigh Feigenbaum Director, Regulatory & Clinical Affairs

Kolltan Pharmaceuticals Board Members (9)

NameRepresentingRoleSinceContact
Info
Arthur Altschul Jr.Kolltan PharmaceuticalsCo-Founder and Chairman000 0000
Axel BolteHBM Healthcare InvestmentsInvestment Advisor000 0000
Daniel Vlock MDSelfDirector000 0000
Frank KarbeKolltan PharmaceuticalsBoard Member000 0000
Gerald McMahon Ph.DKolltan PharmaceuticalsChief Executive Officer, President & Board Member000 0000
Arthur Altschul Jr. Co-Founder and Chairman Kolltan Pharmaceuticals
Axel Bolte Investment Advisor HBM Healthcare Investments
Daniel Vlock MD Director Self
Frank Karbe Board Member Kolltan Pharmaceuticals
Gerald McMahon Ph.D Chief Executive Officer, President & Board Member Kolltan Pharmaceuticals
Request full access to PitchBook